Subsequent survival analyses showed CYP2C8 to be a reliable predictor of OS (Fig. 10 C) and PFI (Fig. 10 D) in the TCGA-BLCA cohort and were validated in the GSE13507 cohort (Fig. 10 E), where we found a better prognosis in the high expression group. This evidence concerns the gene CYP2C8 and bladder transitional cell carcinoma.